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Abstract
Background: Pura is an evolutionarily conserved cellular protein participating in processes of DNA replication,
transcription, and RNA transport; all involving binding to nucleic acids and altering conformation and physical
positioning. The distinct but related roles of Pura suggest a need for expression regulated differently depending
on intracellular and external signals.
Results: Here we report that human PURA (hPURA) transcription is regulated from three distinct and widely-
separated transcription start sites (TSS). Each of these TSS is strongly homologous to a similar site in mouse
chromosomal DNA. Transcripts from TSS I and II are characterized by the presence of large and overlapping 5’-UTR
introns terminated at the same splice receptor site. Transfection of lung carcinoma cells with wild-type or mutated
hPURA 5’ upstream sequences identifies different regulatory elements. TSS III, located within 80 bp of the
translational start codon, is upregulated by E2F1, CAAT and NF-Y binding elements. Transcription at TSS II is
downregulated through the presence of adjacent consensus binding elements for interferon regulatory factors
(IRFs). Chromatin immunoprecipitation reveals that IRF-3 protein binds hPURA promoter sequences at TSS II in vivo.
By co-transfecting hPURA reporter plasmids with expression plasmids for IRF proteins we demonstrate that several
IRFs, including IRF-3, down-regulate PURA transcription. Infection of NIH 3T3 cells with mouse cytomegalovirus
results in a rapid decrease in levels of mPURA mRNA and Pura protein. The viral infection alters the degree of
splicing of the 5’-UTR introns of TSS II transcripts.
Conclusions: Results provide evidence for a novel mechanism of transcriptional control by multiple promoters
used differently in various tissues and cells. Viral infection alters not only the use of PURA promoters but also the
generation of different non-coding RNAs from 5’-UTRs of the resulting transcripts.
Background
The Pur protein family of sequence-specific single-
stranded nucleic acid-binding proteins is extremely well
conserved from bacteria through humans [1]. Human and
mouse Pura differ by only 2 amino acids. Human family
member, Pura, has a primitive codon usage preference
resembling that in bacteria. Pura was first identified due
to its ability to bind a purine-rich sequence in an initiation
zone of DNA replication upstream of the c-MYC gene
[2-4]. It was quickly recognized that Pura has a high affi-
nity for single-stranded oligonucleotides, DNA or RNA,
with a purine-rich repeat, (GGN)n [3]. Pura binds the
G-rich strand of double-stranded DNA [3] with the ability
to locally separate the bound strands [5-7]. Pura’s role in
DNA replication has been supported in several labora-
tories (8-12). Shimotai [8] determined that Pura binds an
element within an autonomously replicating sequence
(ARS) in the rat aldolase B promoter that is essential for
replication. Liu et al. found that Pura and Cyclin A/Cdk2,
two proteins essential for the initiation of replication, are
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MYC gene [9]. Pura has also been associated with viral
DNA replication. Pura binds the JC viral (JCV) origin of
replication and at higher concentrations, inhibits JCV
DNA replication [10]. At lower concentrations Pura coop-
eratively interacts with HIV-1 Tat and large T-antigen to
enhance JCV DNA replication [11,12].
Several papers indicate that Pura is multifunctional in
cell cycle regulation. During early G1, Pura associates
with hypophosphorylated retinoblastoma protein, Rb,
from which it is released when Rb becomes phosphory-
lated in mid to late G1 phase [13]. Pura functions in
maintaining the integrity of replicating DNA [14]. Pura
remains bound to Cyclin A/Cdk2 at the G2/M boundary
[9,15], a checkpoint for replication fidelity. The Cyclin A/
Cdk2 complex is important in the repair of double-strand
breaks [16]. Wang et al. [14] found that mouse embryo
fibroblasts (MEFs) depleted of Pura, have an increased
incidence of double-strand breaks when grown in the
presence of the DNA replication inhibitor hydroxyurea
(HU). Deletions or translocations of PURA correlate with
the occurrence of myelodysplastic syndrome and its tran-
sition to acute myelogenous leukemia [17].
Transcription of a given gene can be initiated at more
than one site. Analyses of full-length human cDNAs from
a large number of cDNA databases has revealed that
human genes, especially those encoding certain proteins
expressed in the brain, have multiple putative alternative
promoters (PAPs) [18]. On average there are 3.1 PAPs per
gene with frequent variation in splicing of the first exon. It
is known that Pura is highly expressed in the brain [19]
and that in the mouse it has one intron in its 5’ untrans-
lated region (5’-UTR). Tissue specificity in the usage of
PAPs was observed [18]. Multiple PAPs allow transcription
to be regulated by different sets of regulatory factors. In
the cases thus far studied, different promoters have gener-
ated different coding sequences. We hypothesize that Pura
expression is controlled differently depending on various
states of cell environment, including growth-altering sig-
nals or viral infection and that such control is mediated
effectively by independent modes of transcriptional promo-
tion. Here we identify three functionally distinct PURA
promoters and show that these are utilized differentially in
human cell types and that they respond differently to cyto-
megalovirus infection. While all three promoters generate
the same protein coding sequence, multiple levels of con-
trol are exerted over the sequences of transcripts produced
and over cellular levels of Pura protein.
Methods
Cell Culture
NCI-H82 and NCI-H146 small-cell lung carcinoma
(SCLC) cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VA) and
were maintained in RPMI medium supplemented with
L-glutamine and antibiotics as described by ATCC. NIH
3T3, a mouse embryonic fibroblast derived cell line was
maintained in culture and infected with mouse cytome-
galovirus (MCMV) as previously described [20].
RNA Analysis
Total RNA from normal lung tissue and lung adenocar-
cinoma (prepared by Clontech, Mountain View, CA)
was used to analyze PURA 5’-UTR RNA. C-DNAs were
synthesized using the ImProm-II Reverse Transcription
System (Promega, Madison, WI) and a primer located
115 nt upstream of the translational start codon.
Sequence closer to the translational start codon was
avoided because of its high G:C content. PURA contain-
ing transcripts were amplified with Taq DNA polymer-
ase as described by Promega in a Hybaid OmniGene
Temperature Cycler. The initial PCR products were pur-
ified on Qiaquick PCR purification columns (Qiagen,
Valencia, CA) and the DNA re-amplified with nested
primers in a reaction mixture made according to the
directions of the Expand HiFidelity PCR System (Roche
Applied Science, Indianapolis, IN) but with the additions
of 5% DMSO and 1.5 μM betaine. Primers prepared by
Invitrogen, (Carlsbad, CA) are described in the text.
Positions and sequences are listed in Table 1.
The MTC™ Panel I (Clontech, Mountain View, CA) of
first strand cDNAs prepared from poly A+ RNA isolated
from eight human tissues was used to quantitate PURA
transcripts. Real time (RT)-PCR was performed using
the ICycler (BioRad, Hercules, CA) with primers
described in the text (also see Table 1) and processed
using ICycler software. RT-PCR reaction products were
routinely analyzed by electrophoresis in 0.8% agarose
gels in 40 mM Tris-Acetate, 2 mM disodium EDTA
(TAE), pH 8.5, and stained with SYBR Gold nucleic acid
gel stain (Molecular Probes, Invitrogen). When reactions
resulted in PCR products of < 200 bp, they were also
analyzed in 8% polyacrylamide gels in the same buffer.
mPura expression in murine cytomegalovirus
(MCMV)-infected cells
NIH 3T3 fibroblasts were propagated and infected with
wild-type Smith strain MCMV as previously described
[20,21]. For the current experiments, cells were infected
with a multiplicity of 2 PFU/cell, and infected cell
lysates were harvested at 1, 3, 5, and 9 hr post infection.
T o t a lc e l lp r o t e i na n dR N Awas isolated using TRI
Reagent (Molecular Research Center, Inc., Cincinnati,
Ohio) according to manufacturer’s instructions. RNA
was further processed using RNAeasy columns (Qiagen)
with DNase I digestion. Mock-infected NIH 3T3 cells
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virus stocks were prepared [21]. The recovered proteins
were separated by 8% SDS-PAGE, and analyzed by
Western immunoblotting. The anti-Pura monoclonal
antibody has been described [22].
PURA promoter reporter constructs, and transfection
To clone the PURA 5’-UTR and promoter sequences,
DNA isolated from normal lung tissue (Oncomatrix, Inc.,
San Diego, CA) was used as template in PCR reactions
using the Expand Hi-Fidelity PCR System (Roche Applied
Science, Indianapolis, IN) with primers chosen to amplify
as e q u e n c ee x t e n d i n gf r o mt h e ATG translational start
codon to a site 2,548 bp upstream (5’-TTTAGGTACCTG
CTACTGTTCGAGCCTGG-3’;5 ’-TTTAAAGCTTT-
GATGCTGCGCTC CGCTGC-3’, Gene Link, Hawthorne,
NY) as above. The amplified sequence was ligated into the
KpnI and HindIII sites in the luciferase reporter gene con-
struct, pGL3-Basic Vector (Promega, Madison, WI) to
produce pGL3-PURAPr. All PURA constructs were made
using this vector, which places the PURA promoter
upstream of the luciferase reporter gene. The PURA
sequence was confirmed by sequencing. The deletion
construct pGL3-PURAPrΔ(-1514 to -1202) was made by
eliminating sequence between the existing restriction sites
PacI and BlpI. Other deletion mutants were made by
synthesizing short sequences, by PCR amplification, on
either side of the intended deletion. The PCR generated
fragments were then ligated to nearby sites generated with
restriction enzymes. These mutants include pGL3-PUR-
APrΔ (-190 to -85); pGL3-PURAPrΔ(-173 to -141); pGL3-
PURAPrΔ(-141 to -85); and pGL3-PURAPrΔ(-141 to -13).
All constructs were grown in XL10-Gold Ultracompetent
Cells (Stratagene, La Jolla, CA). Plasmids were isolated
from bacterial cultures using the EndoFree Maxi Plasmid
Purification Kit (Qiagen, Valencia, CA).
SCLC lines NCI-H82 and NCI-146 were transfected
with pGL3-PURAPr or pGL3-PURAPr mutants and the
expression plasmid pRL-CMV (Promega, Madison, WI),
to determine transfection efficiency, in a medium contain-
ing the transfection reagent Fugene (Roche Applied
Science) according to manufacturer’sd i r e c t i o n s .F o r t y -
eight hours post-transfection, cells were lysed and pro-
cessed for analysis using the Dual-Luciferase Reporter
Assay System, (Promega, Madison, WI). Light emissions
were read in a Turner Designs TD-20/20 Luminometer.
Statistical calculations were obtained using GraphPad
Prism 4.0 for Mac.
Table 1 Primers used in PCR and RT-PCR
Location Primer F/R species 5’base 3’base 5’-t o- 3 ’
TSSI 0 F Hs -6131 -6115 CCCGCAGAGCCTAAAGTGAG
TSSII 1 F Hs -1454 -1435 GGGAGTGGGATCTCTCCTTG
TSSII 2 F Hs -1308 -1289 TCTCCTCCATTCTGGGTCCT
TSSII 3 R Hs -1250 -1268 GGCTAGGGTCTGAATGCTCA
TSSII 4 R Hs -1201 -1220 GAGCCCAGCCTGAGTTGCTG
TSSII 5 F Hs -1135 -1115 CAGTCAGTCGTGGTCCCAAGG
TSSII 6 F Hs -1104 -1086 GCAGGTTTTTGGGTGAGTG
TSSII 7 F Hs -1038 -1018 GGCAGAGTCGACGGGAACAGT
TSSII 8 R Hs -1031 -1049 ACTGTTCCCGTCGACTCTGCC
intron 9 R Hs -913 -933 GTGGCTCTGGCCTCAGATGAT
intron 10 R Hs -842 -824 GCTAGGTGTCTGCTGCTCC
intron 11 R Hs -514 -534 AGCACAGAGAGTGGGCCTAAG
intron 12 F Hs -185 -164 CAGTGCCCTGTTACCGGGTCTC
TSSII&III 13 R Hs -119 -138 CCAGTCAGCCACTCTCGCGA
TSSII&III 14 R Hs -115 -134 ACAGCCAGTCAGCCACTCTC
cds 15 F Hs 780 799 CTACAAGGTGTGGGCCAAGT
cds 16 R Hs 952 933 CTTCCTCACCCTGCAGTAGC
TSSII Mn1 F Mm -1061 -1042 GCAGGTTTTTGGGTGAATGT
TSSII Mn2 F Mm -1003 -984 AGCCTACGGGAATAGGCACT
TSSII Mn3 R Mm -981 -1000 CGCAGTGCCTATTCCCGTAG
Hs - Homo sapiens; Mm - Mus musculus.
All human and mouse primers used in PCR experiments are listed. Their locations upstream from the start codon, direction (F represents the coding strand) and
the features within the promoter near their locations are given. (The locations of primers are illustrated for human, Figure 2A and mouse, Figure 8A).
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transfected cells
The pCAGGs expression vector, which utilizes a
b-actin/b-globin hybrid promoter to express mammalian
genes [23], was used to generate the pCAGGs GFP
expression plasmid by cloning the GFP open reading
frame from pEGFP-C1 (Clontech) into the pCAGGs
vector. Multicloning sites in the amino- and carboxy-
terminal domain of GFP were created to generate NH2
and/or COOH terminal fusions to GFP. Plasmid
pEGFP-C1 hIRF-3 has been previously described [24].
Human IRF-5 was amplified by RT-PCR from RNA iso-
lated from human dendritic cells (kindly provided by
Dr. Nina Bhardwaj, Departments of Medicine, Pathol-
ogy, and Dermatology, NYU Medical Center, NYC, NY)
a n dc l o n e di n t op C A G G s .T h ep E G F P - C 1h I R F - 5p l a s -
mid was generated by subcloning the hIRF5 ORF into
the pEGFP-C1 expression vector. Human IRF-7 was
amplified from the plasmid pBS-hIRF-7A (a gift from
Dr. Luwen Zhang, Center for Virology, University of
Nebraska - Lincoln) and introduced into pCAGGs.
pCAGGs IRF-7-GFP was generated by introducing the
IRF-7 ORF into pCAGGs GFP. Human IRF-1 and IRF-9
were amplified by RT-PCR from RNA isolated from
A549 (lung carcinoma) cells and cloned into pCAGGs.
pEGFP-C1 hIRF-1 and hIRF-9 were generated by sub-
cloning from pCAGGs into pEGFP-C1. Primers used to
amplify the different IRFs are available upon request
from L. Martinez-Sobrido. All constructs were verified
by sequencing. The expression of the GFP-tagged inter-
feron regulatory factors was confirmed by fluorescent
microscopy and by immunoblotting using a GFP mono-
clonal antibody (catalog number 632375) from Clontech.
To analyze the effects of IRFs we used a transfection
system, previously described [24] employing HEK 293T
cells. The reporter plasmids pGL3-PURAPr or pGL3-
hPURAPrΔ(-137 to -85) were cotransfected with GFP-
tagged IRF-1, IRF-3, IRF-5, IRF-7, IRF-9 expression plas-
mids or an empty expression vector using Stratagene’s
(La Jolla, CA) CaPO4 based transfection system.
Twenty-four hours post-transfection, expression of the
GFP tagged constructs was verified by fluorescence
microscopy. Twenty-four hours later, cell lysates were
prepared and the activation of the promoters was deter-
mined using the Luciferase Reporter Assay System.
Chromatin Immunoprecipitation (ChIP) of IRF-3
transfected cells
HEK 293T cells were transfected with pEGFP-C1(hIRF-3)
or pEGFP-C1 control vector as described. Twenty-four
hours later cells were processed for ChIP analysis as pre-
viously described [25] using IRF-3 pAb (catalog number
39033; Active Motif, Carlsbad, CA) designed for use in
ChIP analyses. RT-PCR was performed on the recovered
DNA using primers (see Table 1) chosen to amplify DNA
sequences near TSS II and downstream.
Results
Three distinct regions for the initiation of human PURA
transcription
Because the Pura protein sequence is so highly con-
served [1], we sought to analyze hPURA transcriptional
regulation for clues as to how the regulation of PURA
expression can adapt to important cellular processes. As
hPURA has no TATA-like sequence, there is no single
obvious site for the initiation of transcription. To locate
established PURA transcription start sites (TSSs) we
queried both mouse and human EST databases using
the BLAST algorithm [26]. Because Pura is very widely
distributed in human tissues, the large database of Pura
ESTs provides multiple high-quality sequences. Intrigu-
ingly, the PURA transcripts could be grouped into three
distinct lengths, each of which contains multiple closely-
spaced 5’ends (Figure 1, Table 1). The discrete nature of
these length groups indicates that each corresponds to a
separate transcriptional start site (TSS). The 5’ ends of
the transcripts in TSS I, located most distant from the
translational start codon, correspond to the only thus-
far-demonstrated mouse TSS [27,28]. The sequence sur-
rounding this TSS is strongly conserved in mouse and
humans (Additional file 1, Figure S1) and is, therefore,
Figure 1 Comparison of human (A) and mouse (B) PURA
transcriptional start sites and 5’ untranslated regions. Three
distinct transcriptional start sites (TSSs) initiate transcription of
human PURA. Human and mouse EST databases were utilized to
determine TSSs of PURA. Numbering is from the A in the
translationally- initiating ATG. A. TSS I - III are shown for humans. B.
Two TSSs as determined from ESTs are shown for mouse. The one
most distant from ATG has previously been identified [28]. The new
mouse TSS is very homologous to human TSS III, which is verified in
this report. Human transcripts starting at sites I and II are
characterized by introns of dissimilar lengths, as indicated in A. The
genomic locations of human and mouse PURA are given.
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of TSS I in humans using hPURA promoter specific pri-
mers 0 and 14 (Figure 2A) in rt-PCR analysis of human
lung RNA. These primers, whose 5’ ends are located
6133 and 115 bp respectively, upstream of the transla-
tional start codon, yield an 80 bp rt-PCR product
(Figure 2B). Sequencing this product confirmed the
removal of a 5,939 base intron (Figure 2C). The Group I
transcripts are, therefore, characterized by the removal
of a large intron of 5,481 bp in mouse and 5,939 bp in
human. In both species this intron is completely within
the 5’-UTR. It is not extensively analyzed here, as it has
already been analyzed in the mouse [28].
The 5’ends of a second transcript size group (those
initiated at TSS II) are located approximately 1249 bp
upstream of the translational start codon (Figure 1).
A comparison of Group II transcripts with genomic
DNA reveals that introns of 830 nt are removed from
the 5’-UTRs. This observation essentially controls for
and dispels the notion that these RACE (rapid amplifica-
tion of cDNA ends) products are simply randomly
terminated. Interestingly, removal of the longer intron
in TSS I transcripts eliminates sequences comprising the
5’ ends of the Group II transcripts. Splicing in both
Group I and Group II utilizes a common splice receptor
site (base -143) at the 3’ ends (Figure 1).
Figure 2 Human lung TSS I generates a transcript with a
5’-UTR containing an intron of >5 kb. A. A diagram showing the
locations of all human primers used in Figure 2 and in following
PCR experiments. B. Reverse transcriptase (rt) -PCR analysis of
human lung RNA was performed as described in Methods using
primers 0 and 14 (shown in A. and in Table 1). C. DNA sequencing
was done to demonstrate the position of a 5939 base intron
removed from the transcript. Numbering is as in Figure 1. The
sequence shown is a portion of the full 80 bp band of 2B. Figure 3 Human lung and lung adenocarcinoma cells both
utilize TSS II and splice out an 830 bp intron. A. A diagram
showing the locations of primers used in PCR in Figure 3 and the
size of the resulting PCR products. B. Total RNA from lung (Lu) and
adenocarcinoma of the lung (LuCa) was amplified in rt -PCR
reactions with primers 6 and 14 yielding a 990 bp band (see
Methods). This band is also seen when a DNA sequence containing
PURA was used as template. These bands are not seen in control
reactions, which lacked reverse transcriptase. C. The 990 bp PCR
product was further amplified with two nested primers (10 and 11),
both within the intron of the transcripts from TSS II, yielding a band
of 327 bp. This band is also seen when PURA containing DNA is
used as template (right lane). D. To demonstrate the removal of the
830 bp intron from the primary transcript, cDNA from lung and
adenocarcinoma of the lung was amplified with primer 6 and the
nested primer 13 using shortened extension times. A reaction using
a PURA containing DNA template yielded a 986 bp band (shown at
right). The PCR products from Lu and LuCa cDNA contain a band at
156 bp but essentially no band at 986 bp.
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located within 80 nt of the translational start codon.
This region is particularly rich in GC base pairs (77%).
We considered the possibility that these transcripts may
result from the failure of reverse transcriptase to tran-
scribe through secondary structures that may form in
this GC-rich region.
Analyses which follow in this paper indicate that
Group III transcripts are not abortive RACE products or
processing products, but that their 5’ ends are TSSs
under the control of a unique promoter.
RNA transcripts from human tissues contain PURA 5’-
UTRs originating from TSS Group II
We sought to determine whether TSS II, located 1,249
bp upstream of the Pura translational start codon, is
utilized similarly in normal human lung tissue and lung
adenocarcinoma. PURA promoter specific primers
(shown in Figure 3A) were used to generate cDNA and
then amplify PCR products downstream of the indicated
Group II TSS. DNA upstream of the PURA translational
start codon is particularly rich in G:C base pairs. To
avoid an inhibitory effect on reverse transcriptase, we
chose to initiate cDNA synthesis from a sequence 115
bp upstream of the PURA start codon (Figure 3A).
A second primer binding 989 bp further upstream was
used to amplify the cDNA in PCR reactions. The result-
ing PCR products include a band at approximately 990
bp (Figure 3B). Similar reactions that lacked reverse
transcriptase did not yield this band. These PCR-DNA
products were purified to remove unincorporated oligo-
nucleotides and then reamplified in a second round of
PCR reactions with nested primers. The 327 bp product
o ft h i sr e a c t i o nc a nb es e e ni nF i g u r e3 C ,f i r s t2l a n e s .
Genomic DNA incorporated into the construct pGL3-
PURAPr was utilized in a control reaction. As both pri-
mers (10 and 11, Figure 3A) are located within the
intron, as indicated by the EST databases, the 327 bp
PCR product demonstrates that total RNA as isolated
from lung and lung adenocarcinoma contains transcripts
which include the Group II intron sequence.
The 5’-UTR of the TSS II transcripts is 830 nt shorter
than genomic DNA, raising the possibility of removal of
an intron of that length. If RNA isolated from lung tis-
sue or adenocarcinoma includes mRNA with this dele-
tion, a PCR reaction should generate a product 830 bp
shorter than control DNA. In genomic DNA the pri-
mers (6 and 13) bind at sites 986 bp apart. With the
intron removed, the PCR product would be 156 bp.
A band of 156 bp is seen in Figure 3D. Both normal
lung and adenocarcinoma of the lung contain transcripts
with 5’ start sites at least 1,100 bp upstream of the
translational start codon. The 156 bp PCR-product
affirms that an 830 bp intron is removed from both
lung and lung adenocarcinoma transcripts (Figure 3D).
The intensity of the 156 bp band made from lung ade-
nocarcinoma RNA is clearly greater than the same band
from normal lung. By comparing background bands
whose concentrations are similar, we can surmise that
the greater intensity in the adenocarcinoma is an accu-
rate representation of different levels of spliced tran-
script in these tissues.
PURA TSS II constructs identify sequences acting as a
promoter in a human cell line
T oe v a l u a t et h er o l eo fhPURA promoter sequences on
gene expression, we cloned nearly 2,600 bp of genomic
DNA from the PURA locus, amplified from non-cancerous
human lung DNA, into the luciferase expression vector
pGL3 forming the construct pGL3-hPURAPr. The inserted
PURA sequence extends upstream from the translational
start codon and includes the TSS II located at -1249 bp
(Figure 4A). It does not include TSS I (Figure 4A). PGL3-
hPURAPr was transfected into the small cell lung carci-
noma (SCLC) cell lines NCI-H82 and NCI-H146 along
with a constitutively expressed Renilla luciferase plasmid.
Expression from pGL3-hPURAPr increased 529 fold in
NCI-H82 and 60 fold in NCI-H146 cells over base levels
(Figures 4B), demonstrating that PURA is transcribed
from TSS II in both cell lines.
Elements downstream of TSS II positively control its
transcription
An examination of the PURA promoter by MatInspector
http://www.Genomatix.de, a program developed to iden-
tify transcription factor binding sites, revealed clusters
of transcriptional elements close to both TSS II and
TSS III. Several SP1 binding elements called GC boxes,
an element frequently associated with transcription of
TATA-less promoters, are near both TSSs. TSS II proxi-
mal elements are associated with regulating cellular
innate immunity, including elements for binding
NF-kappaB,, STAT proteins, heat shock proteins, and
interferon regulatory factors (IRFs), which are associated
with inflammation and response to viruses. This group-
ing led us to test the extent to which these elements
function in transcription. To examine this we developed
constructs that deleted selected portions of TSS II or
neighboring sequence (Figure 4A). The construct pGL3-
hPURAPrΔ(-1163 to +1) begins 1400 bp 5’ to the Group
I IT S Sa n de x t e n d s9 5b pb e y o n dr e m o v i n g1 1 5 4b po f
DNA adjacent to the translational start codon. The
removed sequence includes the intron and TSS III
elements. This deletion eliminates all transcription in
H82 and H146 cells (Figure 4A,B). The construct
pGL3-hPURAPrΔ (-1514 to -1202) eliminates a region
including the TSS II and nearby regulatory elements.
Transcription from this construct was reduced to 63%
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clearly a complicated arrangement of stimulatory and
inhibitory elements controlling transcription from TSS
II. While the decrease in transcription from construct
pGL3-hPURAPrΔ (-1514 to -1202) demonstrates that
elements upstream of TSS II have a positive effect on
transcription, the total elimination of transcription from
construct pGL3-hPURAPrΔ(-1163 to +1) in which the
deletion begins 86 bp downstream of TSS II, demon-
strates that elements essential for TSS II transcription in
SCLC H82 and H146 cells are also located downstream
of TSS II. Elements associated with TSS III may thus be
Figure 4 Transfection of the TSS II PURA promoter and promoter deletion constructs demonstrates that sequences within the
promoter are important for PURA transcription. A. The 2554 bp PURA sequence containing TSS II and III as cloned into the pGL3 reporter
vector is shown with transcription factor binding elements, MatInspector (Genomatrix). An identified series of deletion mutants is shown below.
A, B. NCI- H82 and NCI-H146 cells were cotransfected in triplicate with 1.0 μg of the indicated constructs and 0.1 μg pCMV-RL to correct for
transfection efficiency, as described in Methods. Forty-eight hours post-transfection cell lysates were prepared for analysis of luciferase expression
(see Methods). Numbers indicate transcription from pGL3-PURAPr constructs normalized to transcription from pGL3-BV vector. All statistical
analyses were done with two-way ANOVA using the Bonferroni posttest as conducted using Prism 4.0. ***, P < 0.001.
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and were thus examined in detail.
Promoter III contains elements critical for stimulation of
PURA transcription
Several transcriptional elements identified by MatIn-
spector are within 300 bp of TSS III. These include a
CAAT box, an E-box, and binding sites for E2F1, SP1,
NF-Y, and two end-to-end binding sites for Smad4
(Figure 4A). We created the deletion construct pGL3-
hPURAPrΔ (-190 to -85) to eliminate sites for Smad4,
E2F, NF-Y, and the CAAT box. Transcription from this
construct was significantly reduced compared to pGL3-
hPURAPr levels to only 16% in H82 and 25% H146 cells
(Figure 4A,B). To further evaluate these elements we
divided this deletion between two constructs: pGL3-
hPURAPrΔ(-173 to -141), which eliminates the two
Smad4 binding sites and pGL3-hPURAPrΔ(-141 to -85),
which eliminates the E2F/CAAT box. While transcrip-
tion levels of pGL3-hPURAPrΔ(-173 to -141) were
unchanged statistically in H82 and H146, the 53 bp
deletion in pGL3-hPURAPrΔ(-141 to -85) significantly
decreased transcription to 17% and 18%, respectively.
Thus, while the loss of the Smad4 binding sites does not
alter PURA transcription in this system, the E2F/CAAT
region exerts a major influence on PURA transcription.
The Smad4 sites may be used under conditions that
r e q u i r ead i r e c tr e s p o n s et oT G F - b stimuli, and such
conditions may not have existed here. Extending the
deleted sequence to 13 bp upstream of the translational
start codon in pGL3-hPURAPrΔ(-141 to -13) yields a
construct with a similar low level of transcription. This
deletion removes a second E2F binding site, which sup-
ports the conclusion that E2F is an important factor in
regulating transcription from TSS III.
Differential usage of PURA TSS promoter II in different
human tissues
Our results raise the important question of whether or
not utilization of PURA varies in different tissues. To
answer this, we determined the relative quantity of
PURA transcript from the PURA coding sequence (cds-
RNA) compared to transcript for a control RNA,
G3PDH, in 8 human tissues by amplifying in RT-PCR,
cDNA prepared for each tissue (Figure 5, left). The
ΔCts shown represent relative change. Note, that in
Figure 5 each higher Ct indicates a decrease in RNA. In
heart, brain, lung, placenta, and pancreas, the ΔCts of
PURA cds-RNA compared to G3PDH are quite similar.
The levels in two tissues, liver and kidney decrease by
approximately 2Ct (4-fold). Skeletal muscle appears to
have a relatively small amount of PURA compared to
G3PDH (ΔCts = 7.9), although this large difference may
actually reflect the relatively large amount of G3PDH
transcript found in skeletal muscle rather than a
decreased amount of PURA.
To assess the use of TSS II, the relative quantities of 3
sequences within the TSS II transcript and of the PURA
coding sequence RNA (cds) are compared schematically
for each tissue (Figure 5, right). PURA cds RNA may
include transcript originating from any of the three
TSSs and represents the total translatable transcript
within the cell. In contrast, the sequence TSS II-1,
amplified by primers 5 and 8, is located 115 bp down-
stream of TSS II but upstream of the intron (see Figure
2A). All transcripts originating from TSS II should have
this sequence. TSS II-1 would not be found in transcript
originating from TSS I as it is within the intron
removed from TSS I transcripts or in TSS III transcripts
which originate downstream. The relative abundance of
TSS II-1 compared to cds is, therefore, an indication of
the relative amount of transcript originating at this pro-
moter within each tissue. TSS II-1 is utilized most often
in placenta although the decrease in heart and liver is
Figure 5 Relative abundance of PURA transcripts in a panel of
eight human tissues. RT-PCR was performed with 8 human cDNAs
using the indicated PURA specific primers to amplify sequences
downstream of TSS II (TSS II-1, TSS II-2, and TSS II-3) or within the
coding sequence (cds) (see Figure 2A) as described in Methods.
Primers specific to glyceraldehyde 3-phosphate dehydrogenase
(G3PDH) were used to estimate loading. Results are given as the
difference in Ct values (ΔCt) determined by RT-PCR for a designated
amplicon and a control; ΔCt = Ct (cds) - Ct (G3PDH), left panel; ΔCt
= Ct (TSSII-1) or Ct (TSSII-2) or Ct (TSSII-3) - Ct (cds), right panel.
Note that a higher Ct indicates a lower level of transcript by log to
the base 2. Ct values should be seen as indicating the relative
abundance of cDNA amplified by each primer pair and not a
quantitative estimate of the difference in abundance of the cDNA
sequences amplified in a particular tissue.
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Page 8 of 15less than 2-fold. In other tissues brain, lung, and skeletal
muscle, the decrease in abundance of TSS II-1 is at least
5-fold indicating that, in those tissues, TSS I or III yield
more cds transcript. Two other sets of primer pairs
were used to evaluate the frequency at which the intron
is removed from the TSS II transcript. The sequence
TSS II-2 spans the intron donor site. TSS II-3, amplified
by primers 6 and 14, yields a 141 bp product only when
the intron is removed. It is interesting to note that Ct
values for amplicon TSS II-2 are nearly equal to those
of TSS II-1 in heart, lung, liver, skeletal muscle, kidney
and pancreas. Only in brain is the intron removed more
frequently than not. The observation that the TSS II
intron is removed from many brain transcripts indicates
that these rt-PCR products are representative of the
RNA in these tissues, and not contaminating DNA. We
m a yt h u sc o n c l u d et h a tt h eT S SI It r a n s c r i p ti sb o t h
produced and processed differently in different tissues.
Interferon regulatory factors IRF-3, IRF-5, and IRF-7
reduce PURA transcription
PURA TSS II is near several DNA elements that poten-
tially, bind proteins generated and/or activated by an
innate immune response to viral infection. We therefore
determined whether or not interferon regulatory factor
(IRF) proteins, frequently produced or activated as a
result of viral infection, might directly or indirectly alter
use of PURA promoters. To answer this question we
co-transfected HEK 293T cells with GFP-tagged IRF
expression plasmids and the PURA reporter constructs
pGL3-PURAPr or pGL3-PURAPrΔ(-1514 to -1202)
which lacks sequence near TSS II but retains IRF-1 and
STAT1 binding sites. The GFP-tagged IRF plasmids over-
express the IRF-GFP proteins, as seen at 24 hr by the
large amount of GFP contained within the cells when
viewed by fluorescent microscopy. Three of the expressed
proteins IRF-3, IRF-5, and IRF-7, reduced transcription
to between 67% and 17% of control levels in both con-
structs (Figure 6A). The observation that pGL3-PURAPr
and pGL3-PURAPrΔ(-1514 to -1202) in the presence of
IRF-5 and IRF-7 experienced similar decreases in tran-
scription (Figure 6B) suggests that while IRFs 5 and 7
may act at elements near TSS II including ISRE, an IRF
consensus binding element [29], they may act through
other pathways, such as binding elements distal to TSS II
or indirectly though interaction with cellular proteins. In
contrast, IRF-1 increases pGL3-hPURAPr while slightly
decreasing pGL3-hPURAPrΔ(-1514 to -1202) and IRF-9
suppresses pGL3-hPURAPr while having no affect pGL3-
hPURAPrΔ(-1514 to -1202). IRF-1 and IRF-9 are there-
fore the factors most likely to be acting primarily at
elements near TSS II. When pGL3-hPURAPrΔ(-1514 to
-1202) is cotransfected with pEGFP-C1, the control
expression vector, there is an apparent increase, though
not statistically significant, in transcription compared to
pGL3-hPURAPr. This contrasts to the decrease seen fol-
lowing the transfection of pGL3-hPURAPrΔ(-1514 to
-1202) compared to pGL3-hPURAPr into NIH-H82 and
NIH-H146 cells (Figure 4B). Differences in these cell
types may affect their ability to transcribe from the
PURA promoters. This will be considered further in the
Discussion.
Figure 6 Transcription from PURA TSS II is decreased when
cotransfected with IRF expression plasmids. A. HEK 293T cells
were transfected with 0.5 μgo fPURA reporter plasmid, and 4 μgo f
the expression plasmids pEGFP-C1 (hIRF-1, hIRF-3, hIRF-5, hIRF-7, or
hIRF-9) or the control plasmid pEGFP-C1. At twenty-four hours post-
transfection cells were viewed by fluorescent microscopy for the
expression of GFP. At forty-eight hours post-transfection cells were
lysed and analyzed for promoter expression as described in
Methods. Asterisks indicate a significant difference between
transcription from pGL3-hPURAPr and pGL3-hPURAPrΔ((-1514 -1202)
in the presence of the overexpressed IRF protein compared to
vector. B. The transcription of pGL3-hPURAPr and pGL3-hPURAPrΔ
((-1514 -1202) in the presence of the overexpressed IRF proteins is
normalized to their transcription in the presence of vector, which is
set at 100. Asterisks indicate a significant difference between pGL3-
hPURAPr and the deletion construct. All statistical analyses were
done with two-way ANOVA using the Bonferroni posttest. ***, P <
0.001; **, P < 0.01; *, P < 0.05 as conducted using Prism 4.0.
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promoter
Although IRF-3 clearly affects sites distant to TSS II
(Figure 6), because IRF-3 has a distinct inhibitory effect
on PURA expression, we wanted to examine more speci-
fically its effects at TSS II. IRF-3 is normally found in
the cytoplasm of many cell types in an inactive form.
Inducible phosphorylation of IRF-3 allows it to form
homodimers and heterodimers with IRF-7, which are
then transported into the nucleus. In the active (dimer-
ized) state IRF-3 binds to IRF- specific elements in the
DNA. To determine if a DNA sequence near TSS II is
selectively bound by IRF-3, we transfected HEK 293T
cells with the expression plasmid pEGFP-C1-hIRF-3 or
with a control vector pEGFP-C1. Although IRF-3 is nor-
mally present in the cytoplasm, the large increase in
IRF3 would likely facilitate its transcriptional effects.
Twenty-four hours after transfection the cells were pro-
cessed for ChIP analyses. Immunoprecipitations were
carried out with IRF-3 pAb (ActiveMotif) which recog-
nizes chromatin bound IRF-3, or with rabbit IgG.
Primer sets (Figure 7A) were chosen to amplify in RT-
PCR, five sequences located near or downstream of the
TSS II promoter. Enhanced binding of IRF-3 was found
at four of the five sequences tested (Figure 7B). Binding
increased 10.5 fold over control in a 108 bp sequence
(primers 2,4) spanning TSS II. Regions just upstream of
TSS II (primers 1,3) or downstream of the TSS II (pri-
mers 5,8) were amplified to a smaller extent, 3.9 and 1.5
fold respectively. A sequence (primers 12,14) within the
TSS III promoter was amplified only to control levels.
The binding data indicate that sequences close to TSS II
are targeted by IRF-3.
MCMV infection results in a transient decrease in
transcript originating from TSS II
The decrease in expression of pGL3-PURA in the pre-
sence of overexpressed IRF-3, IRF-5, and IRF-7
( F i g u r e6 )a n dt h es p e c i f i cb i n d i n go fI R F - 3t o
sequence near TSS II (Figure 7) led us to investigate
whether or not viral infection could affect PURA
Figure 7 Chromatin-immunoprecipitation (ChIP) analysis of
HEK 293T cells demonstrates that specific sequences near TSS
II bind IRF-3. HEK 293T cells were transfected with pEGFP-C1
(hIRF-3) to overexpress IRF-3 or pEGFP-C1 control vector. After
48 hr cells were fixed as described in Methods and processed for
ChIP analysis. Antibody to IRF-3 or rabbit (Rb) IgG was used to
precipitate chromatin-bound IRF-3. A. DNA sequences amplified
near TSS II and downstream (primers indicated above bars and
given in Table 1). Negative numbers indicate base pairs upstream of
the start codon. B. Quantities of precipitated DNA from cells
transfected with pEGFP-C1(hIRF3) or pEGFP-C1 were determined by
RT-PCR. The DNA precipitated with anti-IRF-3 antibody was
compared to similar DNA precipitated with Rb IgG, which was
considered baseline. Primers for each amplified sequence are given
below.
Figure 8 MCMV infection suppresses PURA transcription and
reduces levels of Pura protein. A. The locations within the PURA
gene of four sequences amplified by the indicated primers (Table 1).
B. The relative concentrations of transcript downstream of TSS II in
MCMV infected NIH-3T3 cells as determined by rt-PCR are shown
relative to concentrations of transcript in mock treated cells (see
Methods). C. Proteins, isolated from the MCMV infected 3T3 cell
lysates used in panel B, were assayed for Pura by immunobloting.
b actin was used as a loading control.
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with MCMV, a virus which activates IRF-3 upon vir-
ion binding to the cell [30]. The similarity of mouse
and human Pura and the PURA promoter sequence
(Additional file 1, Figure S1) render it likely that the
response to MCMV infection by mouse cells would
be similar to that of human cells. Three sequences
within the transcript downstream of TSS II and one
sequence within the PURA coding transcript were
chosen for analysis by rt-PCR. The resulting ampli-
cons are designated by the primers used in their
synthesis (Figure 8A, Table 1). The considerable
homology in mouse and human PURA DNA per-
mitted the use of primers 9, 14, 15, and 16 in PCR
analyses with cDNA from both species. The sequence
Mm1-Mm3 is downstream from the mouse TSS II
and ends upstream of the intron. All transcripts origi-
nating from TSS II should, therefore include Mm1-
M m 3 .T h eq u a n t i t yo ft h i ss e q u e n c ed r o p sr a p i d l y
during the first hour of infection (Figure 8B); a time
when viral particles adhere to cellular receptors and
begin entering the cell. Levels of Mm1-Mm3 tran-
script remain low recovering to the level of mock
treated cells by 9 hours. Changes in the relative quan-
tities of amplicons Mm2-9 and Mm2-14 are indicative
of changes in the processing of the TSS II transcript.
Mm2-9 straddles the intron donor site and is a mea-
sure of unprocessed transcript, i.e., transcript retain-
ing the intron. Mm2-14 is amplified with the same 5’
primer as Mm2-9 but the 3’ primer is located beyond
the intron receptor site. Although the Mm2 and
Mm14 primers should yield amplicons of two sizes; a
898 bp amplicon from the unspliced transcript and a
102 bp amplicon if the intron is removed, in practice
the product is entirely the shorter spliced product, as
can be seen following their separation on a TAE acry-
lamide gel (data not shown). The relative quantity of
transcript Mm2-9 drops quickly following infection, a
decrease that is similar to the decrease in Mm1-Mm3,
but recovers rapidly. At 9 hr pi the level of Mm2-9
exceeds that of mock. In comparison levels of Mm2-
14 drop gradually until 5 hr pi, which may reflect a
slower turnover of this transcript. Levels of Mm2-14
then recover to levels, which at 9 hr pi are lower
than mock. Primers 15 and 16 are located within the
PURA protein coding sequence. Transcription from
all three start sites, TSS I, TSS II, and TSS III, could
extend through sequence 15-16. Amplicon 15-16, cds,
is therefore a measure of all PURA coding transcript
in the cell. The level of cds transcript drops dramati-
cally by 1 hr pi and is only partially recovered at 9 hr
pi. This large drop in cds transcript implies that
synthesis of Pura protein would be reduced signifi-
cantly soon after MCMV infection.
Pura levels drop dramatically following MCMV infection
Decreasing levels of PURA transcript, particularly of
transcript within the coding sequence, raised the ques-
tion of whether or not Pura protein levels also decrease
following MCMV infection. Western blot analysis of
proteins isolated from MCMV infected 3T3 cells at 1
hr, 3 hr, 5 hr, and 9 hr pi, and from mock infected cells
shows that Pura levels drop dramatically shortly after
infection (Figure 8C). At later times Pura levels increase
but continue to remain below mock levels during the
course of the experiment.
The decrease in Pura levels following MCMV infec-
tion requires both the degradation of existing Pura pro-
tein and the discontinuation of new synthesis. The rapid
decrease in cds transcript (15-16) (Figure 8B) as well as
transcript originating from TSS II (Mm1-Mm3) suggests
a coordination in the processes of inhibiting transcrip-
tion from TSS II and of decreasing levels of Pura
protein.
Discussion
These results reveal a novel mechanism for transcrip-
tional regulation of the PURA gene that allows separa-
tion of promoter controls for cell growth signals and
signals for response to viral infection. PURA transcrip-
tion is initiated at three separate start sites that generate
distinct transcripts represented in EST databases. Our
PCR amplification of transcripts from tissues and cell
lines confirms initiation at each of these sites and
reveals that each of the three transcripts is differently
spliced. Promoter usage and alternative splicing differs
among 8 different human tissues examined. Homologies
between these promoters in human and mouse and the
presence of three mouse EST transcripts similar to the
human ones, render it likely that PURA transcriptional
control is similar in both human and mouse. Human
PURA TSS I is furthest upstream of the translational
start site. Because its promoter is very homologous to a
previously characterized mouse promoter [28], we have
not further studied it here. In the mouse, this TSS I pro-
moter is notably subject to feedback regulation by the
Pura protein [28]. Human TSS II is adjacent to an intri-
guing cluster of elements potentially involved in an
innate immune response to viral infection. We have
thus focused here on characterization of promoters II
and III. The results obtained are surprising and raise
important questions potentially relevant to any gene
regulated by multiple promoters. We address some of
those questions here.
Clearly, higher eukaryotes have evolved a transcrip-
tional control mechanism, conserved between human
and mouse, whereby three different promoters generate
transcripts specifying the Pura protein. What evolution-
ary advantage could that confer? One advantage could
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express Pura protein. This type of regulation could be
similar to that observed in polyomaviruses SV40 and
JCV, in which the gene encoding large T-antigen is
under control of multiple promoters. In those cases the
different transcripts are translated at different rates
[31-33]. Another potential advantage could be that the
different PURA RNAs have specific functional pro-
perties. In the rapidly developing field of regulatory
RNA, non-coding RNA, often derived from introns in
5’-UTRs, plays an important regulatory role in mRNA
translation. It is conceivable that the primary aim of the
PURA cellular transcriptional manipulation is to gener-
ate different non-coding RNA species.
Several viruses are reported to co-opt functions of
Pura [12,34]. Is the downregulation of Pura upon
MCMV infection a cellular innate immune response, or
is it an aspect of viral co-opting of a cellular process? In
known instances where Pura function is co-opted by
viruses, e.g., upon infection with HIV-1 or JC virus
[1,35], viral proteins bind to and alter the function of
Pura. That may not be the case regarding certain
aspects of the cellular PURA response to MCMV. The
most dramatic decrease in PURA expression occurs at a
time when a minimal number of MCMV proteins
(immediate early proteins) are synthesized. It remains to
be determined whether later aspects of the cellular
response to MCMV involve co-opting of Pura functions.
The NIH 3T3 cellular response to MCMV infection
involves a very rapid loss of PURA mRNA and Pura
protein. What is the advantage of such a rapid response,
and how is it achieved? Pura i sah i g h l yc o n s e r v e dp r o -
tein that clearly plays a vital role in cell survival [1].
Redundancy of Pur family members is further evidence
for the essential nature of this family [19,36]. The pro-
t e c t i v er o l eo fP u r a against oncogenic transformation is
well documented [13,15,17,37], and it involves rapid
changes in intracellular levels during the cell cycle
[13,15,37]. Therefore, in order to either modulate or co-
opt Pura function, rapid changes in the protein must
ensue. It should be noted that the protein Rb is rapidly
degraded in response to CMV infection [38,39]. Rb is a
well-known binding partner of Pura [13,34,37], and the
two act together to regulate the cell cycle. It is thus con-
ceivable that if Rb is subject to proteolysis, its binding
partner Pura could be exposed to a similar process of
degradation.
The rapid and nearly complete loss of Pura from 3T3
cells within one hour of MCMV infection is intriguing.
MCMV could initiate signaling pathways shortly after
binding to receptors on the cellular membrane. The
integrin receptors are a known point of attachment for
HCMV [40]. The pathways may work through proteins,
which are constitutively present in the cytoplasm and
are integral to the innate immune response. These
i n c l u d ep r o t e i n ss u c ha sI R F - 3 ,w h i c hb e c o m e sp h o s -
phorylated and thus activated upon virion binding to
the cell [30]. We have shown that IRF-3 binds the
PURA promoter and down-regulates PURA transcrip-
tion. Regulatory tegument proteins which are trans-
ported into the cytoplasm on infection may also be
involved [38]. The rapid decrease in levels of both
PURA mRNA and Pura protein would most likely
involve the degradation of both. To reach low levels
within one hour, pre-existing PURA RNA and protein
would need to be destroyed. A transcriptional response
to interferon may not be involved. These findings are
consistent with microarray data indicating that HCMV
infection of monocytes led to a decrease in PURA
mRNA at immediate early times during infection [41].
The significance in the decrease of Pura should be
considered while keeping in mind what is known about
Pura levels during the cell cycle. Pura levels fluctuate
and reach their lowest level at the onset of S-phase [37].
Elevated levels of Pura in NIH 3T3 cells delay entry
into and progression through S-phase [15,42]. It has
been reported that MCMV infection alters the cell cycle
causing rapid progression toward the G1/S boundary
[43,44]. Thus CMV may have evolved a mechanism to
decrease Pura levels in order to further a viral propen-
sity to replicate.
There are multiple processes involved in the PURA
response to MCMV infection. Following the initial
degradation of both Pura and PURA mRNA, there is a
subsequent rapid [40] partial recovery of Pura intracel-
lular levels. This could involve increased translation of
existing PURA mRNA because at this time levels of
such mRNA are still decreasing (Figure 8). It is notable
that levels of Pura protein increase modestly from 3 hrs
through 9 hrs post infection, although levels of its
mRNA are decreasing until at least 5 hrs. It is during
this time that an interferon response to viral mRNA
would be expected. Levels of Pur mRNA and protein
never recover to mock, i.e., uninfected, levels during this
time. Thus, the decrease in overall levels of Pura in
response to MCMV infection is consistent with our data
indicating that IRF proteins repress PURA gene tran-
scription. Experiments beyond the scope of this paper
will be necessary to fully comprehend the multiple com-
ponents of PURA response to viral infection.
The three PURA transcriptional sites identified here as
TSS I, II, and III are approximately 6,404 bp, 1,249 bp,
and 80 bp upstream from the translational start codon,
respectively. Transcripts from TSSs I and II are charac-
terized by the removal of introns of distinctive lengths:
5,939 nt from human TSS I transcripts and 830 nt from
TSS II transcripts. No intron is removed from TSS III
transcripts or from the PURA coding sequence. The
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by different transcriptional elements and with factors
associated with different cellular processes. The role of
the Group II TSS is very intriguing. An analysis of tran-
scription from this site in 8 human tissues revealed that
it contributes to the total PURA transcript differently in
these tissues. Surprisingly, the intron is frequently not
removed from the transcript, and the amount of intron
splicing varies with the different tissues. Only in brain
tissue is the removal of the intron the usual means of
processing. Intron processing also varies between nor-
mal and cancerous tissue as seen when comparing lung
total RNA to RNA from lung adenocarinoma (Figure 3).
While intron RNA is readily detectable in both tissues,
adenocarcinoma has a distinctly greater concentration of
spliced transcript.
An inspection of potential regulatory elements lying
close to TSS II reveals clusters of elements for binding
heat shock factor I and factors associated with viral
infection, such as interferon, IRF-1, NF-kappa B and the
element ISRE which binds the IRF transcription factors.
Considering that Pura is required in many processes
involving ss-RNA or DNA, the presence of these bind-
ing sites suggests that the cell may actually optimize
survival during viral infection by regulating the availabil-
ity of Pura. The ability of the IRFs 3, 5, and 7 to repress
transcription from pGL3-hPURAPr to as low as 27% of
control, supports this hypothesis although these IRFs
did not exclusively act near TSS II. IRF-9 appears to act
primarily at the TSS II promoter (Figure 6). Using ChIP
analysis, we demonstrate that IRF-3 binds a specific
DNA site within the TSS II promoter. The ability of
IRF-3, usually a positive transcriptional regulator, to
down-regulate gene expression has previously been
reported by Grandvaux et al. [45].
Analysis of the total RNA recovered from MCMV
infected 3T3 cells demonstrates that PURA transcription
is altered in response to viral infection. Strikingly, there
is a significant decrease in the processing of TSS II tran-
script, which results in a large increase in the amount of
transcript from which the intron has not been removed.
The binding of IRF-3 and the large number of potential
binding elements near TSS II suggest that this promoter
is regulated by the interferon directed innate immune
response to viral infection. The mechanism of the
altered splicing in this case is unknown, but the overall
effect is similar to that reported for splicing of various
brain transcripts from genes with alternate promoters
[18]. Detailing the mechanism of promoter-specific
altered mRNA splicing, beyond the scope of this study,
will be an important future research subject.
The analyses of transcription from PURA TSS II in
the human tissue panel and in cells transfected in cul-
ture showed that differing cellular environments result
in variable amounts of transcription. Moreover, different
portions of the promoter sequence can affect transcrip-
tion differently in various cell types. This is seen when
comparing transcription from pGL3-hPURAPr Δ(-1514
-1202) in Figure 4 where this deletion mutant gives a
significant reduction in transcription relative to control
vector, whereas in Figure 6, pGL3-hPURAPr Δ(-1514
-1202) yields an increase, not statistically significant, in
transcription. It is notable that Figure 4 was done with
small-cell lung carcinoma cell lines, each of which
highly overexpresses c-MYC [46], and that Figure 6
used HEK 293T cells, which express SV40 large T-anti-
gen (American Type Culture Collection). Each of those
proteins are responsible for multiple cellular changes
that can have different transactivational effects, includ-
ing epigenetic changes in DNA methylation or histone
modifications that can directly affect transcription of
PURA and the deletion mutants [47]. These various epi-
genetic changes affect chromatin conformation causing
sequence to vary in its availability to transactivational
factors. While elements typically bind factors to facilitate
transcription, a different placement of elements could
bind the same factors in an arrangement that results in
steric hindrance and the suppression of transcription. In
t h i sw a yt h eI R F sm i g h tb eu s e dt od e n yi n f e c t i n gv i r -
ions cellular proteins that are essential for their
replication.
Conclusions
In summary, we report that a single PURA gene has
three distinct promoters regulated by factors associated
with different cellular processes including cell growth
and the innate immune response. Two of the promoters
yield long transcripts from which different large introns
are removed. The intron of the 5’UTR from TSS II is
spliced to different degrees in different tissues. IRF-3, 5,
and 7 proteins suppress transcription from TSS II. Fol-
lowing infection by MCMV, the level of PURA tran-
script from TSS II declines rapidly with a corresponding
decrease in level of Pura protein.
Additional material
Additional file 1: Figure S1. The high level of homology of PURA
sequence near TSSI (left) and TSSII (right) in human and mouse
genomic DNA. Sequences were aligned using CLUSTALW multiple
alignment, Pole BioInformatique Lyonnais. Red lettering and asterisks
indicate homologous sequence. Bent arrows indicate transcriptional start
points as identified in EST databases.
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